Ligand Pharmaceuticals Incorporated (LGND) Income Statement: Revenue & Earnings

Ligand Pharmaceuticals Incorporated Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Ligand Pharmaceuticals Incorporated income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	167.13	131.31	196.25	241.54	163.56	120.28	251.45
Cost of Revenue	11.07	10.51	52.83	94.28	30.42	11.35	6.34
Gross Profit	156.06	120.80	143.42	147.26	133.14	108.94	245.12
Operating Expenses
Research & Development	21.43	24.54	36.08	32.11	59.39	55.91	27.86
Selling, General & Administrative	78.65	52.79	70.06	46.79	87.88	41.88	37.73
Operating Expenses	178.67	110.98	140.38	81.01	177.69	126.00	81.39
Operating Income	-22.61	11.94	3.04	66.25	25.85	807.08	163.73
Other Income/Expense
Interest Income	8.06	7.71	2.05	0.89	8.08	0.00	14.00
Interest Expense	3.04	0.66	1.80	-19.62	-27.42	0.00	48.28
Other Income/Expense	25.12	46.78	32.73	-0.35	-0.07	-809.68	43.88
Income
Income Before Tax	2.52	63.66	36.01	72.21	-10.54	796.64	173.33
Income Tax Expense	6.55	9.84	41.23	-4.15	-5.31	167.34	30.01
Net Income	-4.03	52.15	-33.36	57.14	-2.99	629.30	143.32
Net Income - Continuous Operations	-4.03	53.82	-5.22	76.35	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	-1.67	-28.14	-19.22	0.00	0.00	0.00
EBITDA	40.79	99.96	89.34	117.20	56.67	895.83	237.40
EBIT	3.02	64.32	37.81	66.25	28.71	832.38	221.61
Depreciation & Amortization	35.24	2.90	34.24	50.95	1.80	1.50	15.79
Earnings Per Share
Basic EPS	-	3.00	-2.00	3.00	-	21.00	7.00
Diluted EPS	-	3.00	-2.00	3.00	-	20.00	6.00
Basic Shares Outstanding	18.29	17.30	16.87	16.63	25.94	30.45	21.16
Diluted Shares Outstanding	18.29	17.76	16.87	17.25	25.94	31.67	24.07